Drug Patents owned by Allergan Inc

1. Drug name - DURYSTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8629185 ALLERGAN INC 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Jul, 2031

(8 years from now)

CN104367580A ALLERGAN INC Form Ii Of 7 - (3, 5-Dihydroxy - -2-(3-Hydroxy - -5 - Phenyl - -1 - Alkenyl) - Cyclopentyl] - N-Ethyl - -5 - Enamide (Bimatoprost), Preparation Method And Use Method Thereof
Aug, 2017

(5 years ago)

CN102712584B ALLERGAN INC 7-[3,5-Dihydroxy-2- (3-Hydoroxy-5-Phenyl-Pent-1-Enyl)- Cyclopentyl]-N-Ethyl-Hept-5-Enamide (Bimatoprost) In Crystalline Form Ii, Methdo For Preparation, And Method For Use Thereof
Nov, 2030

(8 years from now)

CN102712584A ALLERGAN INC 7-[3,5-Dihydroxy-2- (3-Hydoroxy-5-Phenyl-Pent-1-Enyl)- Cyclopentyl]-N-Ethyl-Hept-5-Enamide (Bimatoprost) In Crystalline Form Ii, Methdo For Preparation, And Method For Use Thereof
Nov, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related implants Apr, 2024

(1 year, 6 months from now)

US8673341 ALLERGAN INC Intraocular pressure reduction with intracameral bimatoprost implants Feb, 2025

(2 years from now)

US9149428 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use Dec, 2026

(4 years from now)

US10441543 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use Dec, 2026

(4 years from now)

US8206737 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods Apr, 2027

(4 years from now)

US7799336 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods Apr, 2029

(6 years from now)

US9980974 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof Oct, 2034

(12 years from now)

US9492316 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof Oct, 2034

(12 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
10MCG IMPLANT;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.